OVERVIEW

We curate the innovations

At Onegene Biotechnology, we are dedicated to making a significant impact on patients' lives by staying at the forefront of research and development. We believe in building upon the work of the pioneers who came before us, and we are constantly striving to push the boundaries of multi-target drug development. With our UniStac^® technology, we have achieved new heights in drug development by breaking free from the constraints of manufacturability, modality choice, and development time. Our approach allows us to unleash the full power of biology, combining the best knowledge and expertise from the field to make an impact for patients suffering from currently untreatable diseases.

Onegene Biotechnology is a preclinical stage biotech established in 2016 and headquartered in Suwon, South Korea. Our unique advantages lie in our expertise in dissecting disease microenvironments and combining chemistry and protein engineering for the best multi-specific mechanisms. With our proprietary technologies, we introduce various target combinations for evaluation in our drug development campaigns, significantly reducing time and cost. Our flagship program, OGB21502, is a tetraspecific drug for NASH treatment, and we are also developing trispecific drugs for IPF and immuno-oncology.